Australia Contrast Agents in MRI Market Size & Outlook, 2025-2033
Australia Contrast Agents in MRI Market Insights
- As per Reed Intelligence insights, the Australia Contrast Agents in MRI Market stood at USD 64.47 Million in 2024 and is anticipated to grow to USD 93.45 Million by 2033.
- The Australia market is expected to advance at a CAGR of 4.24% from 2026 through 2033.
- In 2024, Barium-Based accounted for the highest share of the By Type market size.
- During the forecast period, Gadolinium-Based is set to register the highest growth, making it the most lucrative By Type segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, Australia represented 1.17% of the overall global Contrast Agents in MRI Market size.
- United States is projected to lead the global Contrast Agents in MRI Market size by 2033.
- Across Asia Pacific, China is anticipated to hold the dominant position in market size by 2033.
- Australia is forecasted to expand at the fastest pace in Asia Pacific, attaining USD 93.68 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 64.47 Million |
| Market Size In 2033 | USD 93.45 Million |
| Largest segment | Barium-Based |
| Units | Revenue in USD Million |
| CAGR | 4.24% (2025-2033) |
| Segmnetation Covered | |
| By Type |
|
| By Applications |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Australia Contrast Agents in MRI Market By Type 2025-2033 (USD Million)
| By Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Barium-Based | XX.x | XX.x | XX.x | 24.18 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Iodinated | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Gadolinium-Based | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Microbubble | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Australia Contrast Agents in MRI Market By Applications 2025-2033 (USD Million)
| By Applications | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncology | XX.x | XX.x | XX.x | 22.93 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Cardiology | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Neurology | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Inflammations | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
